Phaseline

Companies › Phoenix Molecular Designs

Phoenix Molecular Designs: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PMD-026
Targeted oral agent for metastatic breast cancer
–Phase 1Metastatic Breast Cancer; Myeloid MalignancyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04115306PMD-026Phase 1Metastatic Breast CancerOncologyDec 2026
NCT07379125PMD-026Phase 1Myeloid MalignancyOncologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.